Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship

Muzîca, Cristina Maria; Sfarti, Cătălin; Trifan, Anca; Zenovia, Sebastian; Cuciureanu, Tudor; Năstasă, Robert; Huiban, Laura; Cojocariu, Camelia; Sîngeap, Ana-Maria; Gîrleanu, Irina; Chiriac, Ştefan; Stanciu, C

doi:10.1155/2020/6638306

Cited by 53 publications

(23 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The bidirectional and mutual relationship between T2DM and NAFLD has been highlighted by epidemiological studies, with NAFLD increasing the risk of T2DM incidence, and T2DM increasing the risk of NAFLD incidence and progression [ 14 ]. A recent meta-analysis showed that the pooled prevalence of NAFLD among adults with T2DM was around 60%, with this prevalence varying by age and by BMI [ 15 ].…”

Section: Discussionmentioning

confidence: 99%

Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged ≥ 40 years

Wang

Zhu

2022

BMC Endocr Disord

View full text Add to dashboard Cite

Background Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease frequently coexist and share pathophysiological manifestations. This study aimed to explore the association between T2DM status and prevalence of liver steatosis and fibrosis, identified using the controlled attenuation parameter and liver stiffness measurement attained via liver ultrasound transient elastography. Methods This was a cross-sectional analysis of data collected in the National Health and Nutrition Examination Survey for 2017–2018. Multivariable logistic regression model was used to evaluate the association between T2DM and prevalence of liver steatosis and fibrosis. Subgroup analyses, stratified by sex age, race, and body mass index (BMI), were further performed. Results Of the 2,780 participants aged ≥ 40 years enrolled, 749 had T2DM, and 2,031 did not. After adjustment for potential confounders, T2DM was associated with a higher prevalence of liver steatosis (OR = 1.7, 95% CI, 1.3–2.1). This T2DM-related prevalence was higher among women (OR = 1.8, 95% CI, 1.3–2.5) and in the non-Hispanic Black (OR = 1.8, 95% CI, 1.1–3.0), other race (OR = 1.9, 95% CI, 1.2–3.0), and BMI < 25 kg/m2 (OR = 2.0, 95% CI, 1.1–3.8) groups. T2DM was also associated with a significantly higher prevalence of fibrosis (OR = 2.0, 95% CI, 1.5–2.7), with this association being more prominent for the other race (OR = 2.9, 95% CI, 1.5–5.5) and BMI < 25 kg/m2 (OR = 3.3, 95% CI: 1.3–8.8) groups. Conclusions Our findings indicated a positive association between T2DM status and prevalence of hepatic steatosis and fibrosis. This association was more prominent for individuals with a BMI < 25 kg/m2 and was influenced by race-specific effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged ≥ 40 years

Wang

Zhu

2022

BMC Endocr Disord

View full text Add to dashboard Cite

show abstract

“…Several epidemiological studies have reported an association between diabetes and NAFLD. Recent evidence supports a more complex link between diabetes and NAFLD than was previously observed, exhibiting a bidirectional and mutual association between them (24). NAFLD has been reported to be a risk factor for type 2 DM (T2DM), and T2DM is a risk factor for liver disease in patients with NAFLD (6,25,26).…”

Section: Discussionmentioning

confidence: 68%

Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease

Xiang

Chen

2021

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectiveThe influence of diabetes on mortality among patients with non-alcoholic fatty liver disease (NAFLD) in the general population has not been extensively studied. This study aimed to determine the relationship between diabetes and all-cause and cardiovascular mortality in patients with hepatic ultrasound-confirmed NAFLD using data from the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994.MethodsData from 4,037 adult individuals with NAFLD from the NHANES III and mortality outcomes linked to National Death Index records through December 31, 2015, were included. Cox proportional hazards models were used to calculate the hazard ratio (HR) and corresponding 95% CI for mortality from all causes and cardiovascular disease after adjusting for multiple variables.ResultsAmong 4,037 subjects with NAFLD (55.9% female), 483 had diabetes at baseline. During a median follow-up of 22.1 years, 1,517 (11.5%) died, including 332 (8.22%) from cardiovascular causes. Diabetes was associated with increased all-cause (HR 3.02 [95% CI 2.67–3.41]) and cardiovascular (HR 3.36 [95% CI 2.61–4.32]) mortality in an unadjusted multivariable Cox regression model. The association remained statistically significant after adjusting for a range of potential confounders (HR 2.20 [95% CI 1.90–2.55] for all-cause mortality and HR 2.47 [95% CI 1.81–3.37] for cardiovascular mortality). An additional stratified analysis did not reveal significantly altered results.ConclusionDiabetes was associated with all-cause and cardiovascular mortality in patients with NAFLD. This link could be further characterized in future studies assessing the degree of glycemic control and its relationship with mortality in patients with diabetes and NAFLD.

show abstract

“…NAFLD is the major chronic liver disease in the world and represents the hepatic symptom of MetS [127,128]. NAFLD affects one in four adults and is expected to increase annually in parallel with the increase in MetS prevalence [129]. NAFLD is defined as the appearance of hepatic steatosis with the absence of causes for secondary hepatic fat accumulation, such as excessive alcohol consumption, use of steatogenic prescriptions, or any hereditary disorder [130].…”

Section: Non-alcoholic Fatty Liver Disease (Nafld)mentioning

confidence: 99%

Propolis in Metabolic Syndrome and Its Associated Chronic Diseases: A Narrative Review

et al. 2021

View full text Add to dashboard Cite

Propolis is a resinous product collected by bees from plants to protect and maintain the homeostasis of their hives. Propolis has been used therapeutically by humans for centuries. This review article attempts to analyze the potential use of propolis in metabolic syndrome (MetS) and its associated chronic diseases. MetS and its chronic diseases were shown to be involved in at least seven out of the top 10 causes of death in 2019. Patients with MetS are also at a heightened risk of severe morbidity and mortality in the present COVID-19 pandemic. Propolis with its antioxidant and anti-inflammatory properties is potentially useful in ameliorating the symptoms of MetS and its associated chronic diseases. The aim of this article is to provide a comprehensive review on propolis and its therapeutic benefit in MetS and its chronic diseases, with an emphasis on in vitro and in vivo studies, as well as human clinical trials. Moreover, the molecular and biochemical mechanisms of action of propolis are also discussed. Propolis inhibits the development and manifestation of MetS and its chronic diseases by inhibiting of the expression and interaction of advanced glycation end products (AGEs) and their receptors (RAGEs), inhibiting pro-inflammatory signaling cascades, and promoting the cellular antioxidant systems.

show abstract

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship

Cited by 53 publications

References 54 publications

Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged ≥ 40 years

Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged ≥ 40 years

Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease

Propolis in Metabolic Syndrome and Its Associated Chronic Diseases: A Narrative Review

Contact Info

Product

Resources

About